Nkarta, Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; comparisons are with FY2019 unless noted. The filing was signed March 25, 2021. Nkarta is a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. It has no approved products and has never generated product-sales revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0.115 million |
| Research and development expense | $36.220 million | $17.217 million |
| General and administrative expense | $15.288 million | $5.247 million |
| Operating loss | $51.508 million | $22.349 million |
| Net loss | $91.361 million | $21.076 million |
| Net loss per share, basic and diluted | $5.44 | $14.41 |
| Net cash used in operating activities | $43.506 million | $18.367 million |
- FY2020 net loss included a $40.163 million noncash expense from remeasuring a preferred-stock purchase-right liability, which was settled and reclassified to equity in July 2020. This was the principal reason net loss rose substantially more than operating loss.
- At year-end, cash and cash equivalents were $96.692 million, short-term investments were $218.221 million, and restricted cash was $0.413 million—approximately $315.3 million combined. Current assets were $318.835 million versus current liabilities of $8.831 million.
- Total liabilities were $16.430 million, including $8.919 million of operating lease liabilities. The filing reports no outstanding borrowings at year-end.
- Nkarta reported a $118.021 million accumulated deficit. There is no meaningful product margin; profitability and operating margins are not applicable to this pre-commercial business.
- Financing included $265.1 million net proceeds from the July 2020 IPO and $64.3 million net proceeds from the second Series B preferred-stock financing. IPO proceeds were invested in cash equivalents and marketable securities; the company reported no material change to the planned use of proceeds.
- Management said available cash, cash equivalents, restricted cash and short-term investments were expected to fund operations for at least 12 months from the filing date. The company expects substantial ongoing losses and says additional financing will be needed to execute its longer-term plans.
Material changes versus FY2019
- Operating expenses increased by $29.044 million: R&D rose $19.003 million and G&A rose $10.041 million. R&D growth reflected increased personnel, external program costs and internal research expenses; G&A growth included public-company costs, higher personnel and a $2.3 million stock-option modification charge related to the former CFO.
- Operating cash use increased by $25.139 million as development activity expanded. Investing cash use was $210.081 million, primarily reflecting purchases of short-term investments funded by financing proceeds, plus $7.511 million in property and equipment purchases, including manufacturing-facility construction.
- Nkarta completed its IPO, began trading on Nasdaq in July 2020, and converted all outstanding preferred stock into common stock upon the IPO closing.
- NKX101 advanced into its first-in-human Phase 1 trial, with the first patient treated in November 2020. Construction of a 2,700-square-foot clinical cGMP facility was completed in 2020.
Outlook, management commentary and risks
- Pipeline: NKX101 is in Phase 1 dose-finding for relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). Nkarta planned to submit an NKX019 IND in Q1 2021 and expected first patient dosing in the second half of 2021. It expected an IND for a third CAR-NK candidate in 2022 and for an NK-plus-T-cell program in 2023; these were forward-looking plans, not achieved results as of the filing.
- Manufacturing: The South San Francisco clinical facility was undergoing qualification, with NKX019 production expected to begin in 2021 and NKX101 production planned for 2022. A separate, larger facility for pivotal trials and potential commercial supply was still in design and site evaluation. The company estimated a potential commercial manufacturing cost of about $2,000 per dose at peak capacity; this was an estimate based on stated production assumptions, not demonstrated commercial economics.
- COVID-19: Restrictions and infections at some contract manufacturing sites caused delays, and the company reported delays in facility construction and internal research early in 2020. Management said the pandemic had not materially changed the announced NKX101 milestones and did not expect a material impact on the NKX019 IND timeline, while warning that later effects on trials, vendors and timelines remained uncertain.
- Key risks: The technology is novel and unproven in humans; NKX101 was the only candidate tested in patients, and clinical efficacy and safety remain unknown. Trials may be delayed, fail or reveal serious adverse events. Other risks include manufacturing scale-up and cryopreservation, dependence on third-party suppliers and a sole supplier for certain manufacturing equipment and reagents, funding needs and potential dilution, competition, regulatory and reimbursement uncertainty, and dependence on licensed intellectual property.
- The company reported no pending legal matter that management considered likely to have a material adverse effect. A third-party patent re-examination remained pending for a patent that the filing says does not relate to current candidates but may relate to future programs. Disclosure controls were judged effective at a reasonable-assurance level; the filing did not include management’s internal-control effectiveness assessment because of the newly public company transition period.
Important facts for investors to verify
- Current cash, investment balances and actual cash burn against management’s stated runway, including the timing and cost of planned clinical trials and manufacturing expansion.
- NKX101 trial enrollment, safety, persistence and efficacy data, and whether off-the-shelf dosing can work without donor-recipient HLA matching.
- Whether NKX019’s IND and trial milestones occurred as planned, and whether manufacturing-facility qualification and production timelines were met.
- Whether the estimated manufacturing cost, scale, cryopreserved-product stability and supply assumptions can be demonstrated in practice.
- Potential dilution from future financing and equity awards, plus developments in the patent re-examination and the company’s licensed intellectual property rights.